Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis PatientsPRNewsWire • 06/29/21
AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO)PRNewsWire • 06/28/21
FDA To Miss Action Dates For AbbVie's Upadacitinib Application For Psoriatic Arthritis, Ankylosing SpondylitisBenzinga • 06/25/21
AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.PRNewsWire • 06/25/21
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic DermatitisPRNewsWire • 06/25/21
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple MyelomaPRNewsWire • 06/24/21